qualyfast®SARS-CoV-2 Multiplex qPCR IVD Kit

Supplier: Bioside

BSIDA3.01053EA 1600 EUR
BSIDA3.01053 BSIDA3.21053 BSIDA3.11053
qualyfast®SARS-CoV-2 Multiplex qPCR IVD Kit
Clinical Diagnostic Systems Clinical reagents and kits
qualyfast®SARS-CoV-2 Multiplex products are rapid, sensitive, specific, reproducible and ready to use kits for detection of SARS-CoV-2 (COVID-19 virus) from biological fluids and swabs. They develop reliable and accurate diagnostic assays, essential for healthcare systems.

  • Permits a simultaneous and specific detection of two targets: Gene S and gene RdRP of SARS-CoV-2
  • Highlights a possible effect of inhibition in the RNA from the sample thanks to an included RNA Inhibition Amplification Control

RNA detection is done by One Step Real-Time PCR using dye labelled probes, where the reverse transcription and the subsequent amplification of specific target sequence occur in the same reaction well. The kits allow a sensitive and specific One-Step RT qPCR-based multiplex assay.

qualyfast®SARS-CoV-2 Multiplex product is:
- Pre-dosed and lyophilised in the reaction tubes
- Individually packed in strips of eight
- Stable for shipment and storage at room temperature
- WHO guidelines complaint - compatible with leading open system Real-Time qPCR instruments
- Compatible with manual and automated RNA extraction systems

The kits are validated on CFX96 (Biorad) and Quant Studio (Thermo Fisher), they are also able to safely detect RNA using all common real-time PCR devices.

The clinical performance of qualyfast®SARS-CoV-2 Multiplex and Multiplex 2 products were tested using more than 100 respiratory specimens (nasopharyngeal swabs and biological fluids) from patients. These results were compared with those obtained with the molecular detection method of the protocol “2019-nCoV by real-time RT-PCR” suggested by Charité (Berlin), with modifications). Sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for qualyfast®SARS-CoV-2 Multiplex detection kit compared with Charité protocol are >99,9%.

Results show high sensitivity and specificity to detect SARS-CoV-2. Detection limit IS ≥10 RNA copies per reaction. The specificity of the SARS-CoV-2 assay was confirmed by testing a panel consisting of different microorganisms representing the most common respiratory pathogens. No cross-reactivity was detected between any of the microorganisms tested.

Certifications: qualyfast®SARS-CoV-2 Multiplex products are for In Vitro Diagnostic Use (CE IVD Mark).

Delivery information: Each kit is provided as 12 individually packed strips of 8 tubes; DNA free solution tube for rehydratation; one additional strip of 8 reaction tubes of positive controls ready to use.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR